Effect of Montelukast Sodium in Conjunction with Mometasone Furoate Aqueous Nasal Spray in Treating Allergic Rhinitis

To observe the efficacy of montelukast sodium tablets in conjunction with mometasone furoate aqueous nasal spray in treating allergic rhinitis. Within the period spanning from September 2022 to September 2023, our hospital admitted 100 patients diagnosed with allergic rhinitis, forming the study population. After randomization, the individuals were allocated into either the control group or the observation group, both consisting of equal numbers of 50 cases. The control group was administered solely with mometasone furoate aqueous nasal spray, whereas the observation group received a combined treatment consisting of montelukast sodium tablets and mometasone furoate aqueous nasal spray. Following a 14 d period of consistent treatment, a comparison was made between the two groups regarding their clinical treatment effectiveness, visual analog scale scores, cellular immune levels, and serum cytokine levels. The overall effective rate in the observation group reached 94.00 %, displaying a remarkable increase compared to the control group's rate of 74.00 % (p<0.05). Prior to intervention, no marked disparity in visual analog scale scores existed in both groups (p>0.05). However, following treatment, both groups showed decreased visual analog scale scores, and the observation group exhibited lower scores than the control group, revealing a marked distinction (p<0.05). The levels of interleukin-4, interleukin-8, and interferon-gamma showed no remarkable variation between the two groups prior to treatment (p>0.05). Subsequent to treatment, the observation group showed lower levels of interleukin-4 and interleukin-8 in contrast to the control group, whereas the interferon-gamma level in the observation group noticeably elevated. These findings indicate a remarkable difference (p<0.05). The control group (16.00 %) and the observation group (18.00 %) both exhibited adverse reactions such as nasal dryness, nasal mucosal bleeding, rash, and insomnia. However, there was no notable difference in the occurrence rate of these adverse reactions between the two groups (p>0.05). The concurrent administration of mometasone furoate aqueous nasal spray and montelukast sodium tablets signifies a remarkable therapeutic breakthrough for allergic rhinitis treatment. This combination therapy not only effectively ameliorates symptoms but also improves immune markers, all while ensuring the risk of adverse reactions remains minimal.